Trials / Not Yet Recruiting
Not Yet RecruitingNCT06595797
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
Randomized, double-blind, placebo-controlled study of HRS9531 in PCOS subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS9531 | HRS9531 |
| DRUG | HRS9531placebo | HRS9531placebo |
Timeline
- Start date
- 2024-09-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2024-09-19
- Last updated
- 2024-09-19
Source: ClinicalTrials.gov record NCT06595797. Inclusion in this directory is not an endorsement.